Skip to main content
OpenTrials
Completed

NCT Number: NCT06195137

Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.)

The aim of this study was to evaluate the efficacy of caffeine and alpha-lipoic acid in the treatment of burning mouth syndrome by symptom assessment with visual analogue scale.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

West China Hospital of Stomatology, Sichuan University

Chengdu, 610041, China

About this study

The etiology of BMS is multifactorial, involving a complex interplay of neuropathic, psychological, neuroendocrine, and immunological factors. Neurologically, BMS has been categorized into three subtypes: peripheral small fiber neuropathy, subclinical trigeminal neuropathy, and inhibitory dopaminergic deficiency. Neuroimaging and peripheral nerve studies have further implicated altered brain activation patterns and increased expression of specific receptors like TRPV1 and P2X3 in the pathogenesis of BMS. Hormonal imbalances, particularly in estrogen levels, have also been suggested to contribute to contribute to the condition.

Caffeine, a xanthine alkaloid chemically known as 1,3,7-trimethylxanthine, is recognized for its diverse biological functions. As a central nervous system stimulant, its primary mechanism involves antagonizing adenosine receptors, thereby enhancing the release of neurotransmitters such as dopamine and norepinephrine, which are known to play roles in analgesic pathways. Caffeine is also noted for its neuroprotective properties and is theorized to reduce the risk of neurodegenerative diseases. It affects the central processing of pain and is involved in regulating circadian rhythms and sleep-wake cycles. Additionally, caffeine has mild anti-inflammatory properties. Its stimulatory effects may also improve mood and cognitive function.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults over 18 years of age
  • Diagnosis of BMS according to the 3rd edition of the International Classification of Headache Disorders (ICHD-3)
  • Daily intraoral burning or dysaesthesia lasting for more than 2 hours for over 3 months
  • Normal oral mucosa and sensory testing
  • Condition not better accounted for by another ICHD-3 diagnosis

Exclusion criteria

  • Secondary BMS due to local or systemic disorders
  • Prior treatment for BMS
  • Psychiatric or progressive neurological disorders
  • Systemic disorders potentially associated with oral disease
  • Long-term history of smoking, drinking, or medication use
  • Consumption of caffeinated products
  • Poor oral hygiene
  • Abnormal blood test results (including blood count, glucose, serum iron, ferritin and transferrin, folic acid, or vitamin B12 levels)
  • Incomplete medical records
  • Unwillingness to participate

Treatment and study plan

Caffeine

Dietary Supplement

caffeine supplementation

Alpha lipoic acid

Drug

600-800 mg ALA

Other names: ALA

Primary outcomes

  1. Visual Analogue Scale (VAS)

    Time frame: Baseline and 2 weeks after intervention or observation

    During the interview or telephone follow-up with the patient, ask the patient to fill in the VAS rating scale.

Sponsors and collaborators

Lead sponsor

Lu Jiang

Other

Registry information

Official study title

Efficacy of Caffeine vs. Alpha-Lipoic Acid in Burning Mouth Syndrome Treatment

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Jan 8, 2024
Registry last updated
Jan 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.